Tone mix
Week by week 52 weeks
Share of Axsome Therapeutics, Inc's 184 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Aug 3, 2026 · tone -100Axsome Therapeutics (NASDAQ:AXSM) Stock Price Down 4% After Analyst Downgrade-139
- Week of Sep 8, 2025 · tone +100Axsome Therapeutics Stock Sees RS Rating Rise To 82+78
- Week of Jun 22, 2026 · tone +97Axsome Therapeutics (NASDAQ:AXSM) Hits New 1-Year High on Analyst Upgrade+76
- Week of Sep 15, 2025 · tone +100Axsome Therapeutics, Inc. (AXSM) Stock Analysis: Exploring A Potential 49% Upside In The Biotech Sector+72
- Week of May 11, 2026 · tone +98Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer's Agitation Launch+61
- Week of Jul 20, 2026 · tone +100Axsome Therapeutics' (AXSM) "Buy" Rating Reiterated at HC Wainwright+60
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Axsome Therapeutics, Inc in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 4 | 0 |
| Last 30 sessions | 18 | +11 |
| Last 90 sessions | 48 | +22 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Thursday, October 29, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.fool.com · 2 outletsAxsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp VolatilityNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility | www.fool.com | 2 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 27, 2026
3 headlines, average tone 0: 0 positive, 3 neutral and 0 negative. Showing all 3.
- www.tickerreport.com · 1 outletReviewing Ensysce Biosciences (NASDAQ:ENSC) and Axsome Therapeutics (NASDAQ:AXSM)Neutral
- www.dailypolitical.com · 1 outletReviewing Axsome Therapeutics (NASDAQ:AXSM) and Ensysce Biosciences (NASDAQ:ENSC)Neutral
- www.dailypolitical.com · 1 outletEquities Research Analysts' Price Target Changes for October 26th (AARD, ACG, ACR, AMR, APLE, ASIC, AXON, AXP, AXSM, BAH)Neutral
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Reviewing Ensysce Biosciences (NASDAQ:ENSC) and Axsome Therapeutics (NASDAQ:AXSM) | www.tickerreport.com | 1 | Neutral |
| Reviewing Axsome Therapeutics (NASDAQ:AXSM) and Ensysce Biosciences (NASDAQ:ENSC) | www.dailypolitical.com | 1 | Neutral |
| Equities Research Analysts' Price Target Changes for October 26th (AARD, ACG, ACR, AMR, APLE, ASIC, AXON, AXP, AXSM, BAH) | www.dailypolitical.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 14, 2026
2 headlines, average tone 0: 0 positive, 2 neutral and 0 negative. Showing all 2.
- www.themarketsdaily.com · 1 outletAnalysts' Weekly Ratings Updates for Axsome Therapeutics (AXSM)Neutral
- www.insidermonkey.com · 1 outletAxsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For?Neutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Analysts' Weekly Ratings Updates for Axsome Therapeutics (AXSM) | www.themarketsdaily.com | 1 | Neutral |
| Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For? | www.insidermonkey.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 13, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.fool.com · 2 outletsWhere Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's?Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? | www.fool.com | 2 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 8, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.fool.com · 2 outletsAxsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026? | www.fool.com | 2 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Axsome Therapeutics, Inc, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.